Influenza Vaccines Market, 2023 – Market Outlook, Competitive Analysis, Industry Trends
Qurate Research announces the addition of new study based research report on “Influenza Vaccines Market” to their suite of offerings.
(EMAILWIRE.COM, October 13, 2018 ) This report covers the present scenario (with the base year being 2017) and the growth prospects of Global Influenza Vaccines Market Report for 2018-2023.
Influenza vaccines, also known as flu shots or flu jabs, are vaccines that protect against infection by Influenza viruses. A new version of the vaccine is developed twice a year, as the Influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The CDC estimates that vaccination against influenza reduces sickness, medical visits, hospitalizations, and deaths. When an immunized worker does catch the flu, they are on average back at work a half day sooner. Vaccine effectiveness in those under two years old and over 65 years old remains unknown due to the low quality of the research. Needs update][8][needs update] Vaccinating children may protect those around them.
The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend yearly vaccination for nearly all people over the age of six months, especially those at high risk. The European Centre for Disease Prevention and Control also recommends yearly vaccination of high risk groups. These groups include pregnant women, the elderly, children between six months and five years of age, those with other health problems, and those who work in healthcare.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-58926
The vaccines are generally safe. Fever occurs in five to ten percent of children vaccinated. Temporary muscle pains or feelings of tiredness may occur as well. In certain years, the vaccine has been linked to an increase in Guillain–Barré syndrome among older people at a rate of about one case per million doses. It should not be given to those with severe allergies to eggs or to previous versions of the vaccine. The vaccines come in both inactive and weakened viral forms. The inactive version should be used for those who are pregnant. They come in forms that are injected into a muscle, sprayed into the nose, or injected into the middle layer of the skin.
Vaccination against influenza began in the 1930s with large scale availability in the United States beginning in 1945. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale price in the developing world is about $5.25 USD per dose as of 2014.In the United States, it costs less than $25 USD as of 2015.
Over the next five years, LPI(LP Information) projects that Influenza Vaccines will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017. This report presents a comprehensive overview, market shares, and growth opportunities of Influenza Vaccines market by product type, application, key manufacturers and key regions.
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-58926
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Trivalent Flu Vaccines
Quadrivalent Flu Vaccines
Segmentation by application:
Adults
Pediatrics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Enquiry For Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-LPI-HnM-58926
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
AstraZeneca
CSL
GlaxoSmithKline
Sanofi
Altimmune
BionVax
FluGen
FOLIA BIOTECH
Genentech
Green Cross
Medicago
Moderna Therapeutics
Novavax
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Direct Purchase@ https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-58926/
Influenza vaccines, also known as flu shots or flu jabs, are vaccines that protect against infection by Influenza viruses. A new version of the vaccine is developed twice a year, as the Influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The CDC estimates that vaccination against influenza reduces sickness, medical visits, hospitalizations, and deaths. When an immunized worker does catch the flu, they are on average back at work a half day sooner. Vaccine effectiveness in those under two years old and over 65 years old remains unknown due to the low quality of the research. Needs update][8][needs update] Vaccinating children may protect those around them.
The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend yearly vaccination for nearly all people over the age of six months, especially those at high risk. The European Centre for Disease Prevention and Control also recommends yearly vaccination of high risk groups. These groups include pregnant women, the elderly, children between six months and five years of age, those with other health problems, and those who work in healthcare.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-LPI-HnM-58926
The vaccines are generally safe. Fever occurs in five to ten percent of children vaccinated. Temporary muscle pains or feelings of tiredness may occur as well. In certain years, the vaccine has been linked to an increase in Guillain–Barré syndrome among older people at a rate of about one case per million doses. It should not be given to those with severe allergies to eggs or to previous versions of the vaccine. The vaccines come in both inactive and weakened viral forms. The inactive version should be used for those who are pregnant. They come in forms that are injected into a muscle, sprayed into the nose, or injected into the middle layer of the skin.
Vaccination against influenza began in the 1930s with large scale availability in the United States beginning in 1945. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale price in the developing world is about $5.25 USD per dose as of 2014.In the United States, it costs less than $25 USD as of 2015.
Over the next five years, LPI(LP Information) projects that Influenza Vaccines will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017. This report presents a comprehensive overview, market shares, and growth opportunities of Influenza Vaccines market by product type, application, key manufacturers and key regions.
For Enquiry, Visit@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-LPI-HnM-58926
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Trivalent Flu Vaccines
Quadrivalent Flu Vaccines
Segmentation by application:
Adults
Pediatrics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Enquiry For Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-LPI-HnM-58926
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
AstraZeneca
CSL
GlaxoSmithKline
Sanofi
Altimmune
BionVax
FluGen
FOLIA BIOTECH
Genentech
Green Cross
Medicago
Moderna Therapeutics
Novavax
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Direct Purchase@ https://www.qurateresearch.com/report/buy/HnM/QBI-LPI-HnM-58926/
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results